Antinuclear antibody (ANA) patterns (using HEp-2 ANA assay kit) and anti-dsDNA (analysed by Crithidia luciliae assay) in sera of the lpr-water, lpr-CU.

Slides:

Advertisements

Similar presentations

Performance Characteristics of the FARRZYME™ High Avidity Anti-dsDNA IgG Antibody ELISA Brenda B. Suh-Lailam 1, Tyson R. Chiaro 1, K. Wayne Davis 1, Andrew.

Advertisements

Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Figure 2 Expression of complement activation products in renal samples

Figure 4 Antinuclear antibodies and disease activity in SLE

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Figure 1 IFA testing for identifying the presence of ANAs

(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Clinical and serological evolution of the presented case.

Volume 16, Issue 4, Pages (April 2002)

The absence of ADCC by nivolumab in vitro.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Association of pretreatment interferon (IFN) signature metric (ISM) status with serum autoantibodies, BAFF levels and type I IFN bioactivity. Association.

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but.

Suggested diagnostic protocol for investigation of suspected SLE

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Fig. 3. Knockdown of cited3 results in increased cell death but it does not affect proliferation.Embryos that are injected with the control MO (A–C), cited3.

Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed.

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Performance characteristics for multivariate assay SLE panel.

Positivity rate for antibodies to double-stranded DNA (anti-dsDNA), low complement, high complement C4 activation products (CBCAPS) and two-tiered methodology.

Anifrolumab does not elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. Anifrolumab does.

Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

Anti-RNP/anti-Sm antibodies in sera (bleeds 1–5) and H&E stained sections of kidney/salivary gland of the MRL-lpr/lpr and MRL-MpJ mice provided with water,

Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.

Urinary cell casts, lymph node weights and proteinuria in the lpr-water, lpr-CU and lpr-TU groups of mice. Urinary cell casts, lymph node weights and proteinuria.

Silver-stained gel showing the major tyrosine-phosphorylated proteins in podocytes. Silver-stained gel showing the major tyrosine-phosphorylated proteins.

Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.

Effect of dose level on the anti-keyhole limpet haemocyanin (KLH) IgG response in the multiple-ascending dose (MAD) study. Effect of dose level on the.

The effect of purified IgG from healthy controls or patients with lupus nephritis on tyrosine phosphorylation in podocytes at two different IgG concentrations.

Complement and antibody abnormalities at baseline and relation to disease activity clinical SELENA-SLEDAI (A) and PGA scores (B) in relation to the presence.

Tyrosine phosphorylation of proteins in podocyte lysates following exposure to healthy or lupus nephritis plasma. Tyrosine phosphorylation of proteins.

Change in urinary protein to creatinine ratio (uPCR) as a function of serum C4, C3, anti-C1q, EC4d, EC3d and ECR1. Change in urinary protein to creatinine.

Distribution of the RAMRIS component scores sorted by pain score.

Association of MRI findings and serum autoantibodies in diffuse neuropsychiatric systemic lupus erythematosus. Association of MRI findings and serum autoantibodies.

SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.

Anti-DNA Abs were not affected by the deletion of GCs in pristane-induced lupus model. Anti-DNA Abs were not affected by the deletion of GCs in pristane-induced.

Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Two-tier.

Least squares (LS) mean (SE) changes from baseline in (A) Cutaneous Lupus Erythematosus Disease Area and Severity Index activity scores and (B) Tender.

Antibody levels to Ro52, Ro60, p200 and La antigens in control and congenital heart block (CHB) cohort were measured as bound units (BU). Antibody levels.

Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.

Presence of autoreactive anti-HLA antibodies among SLE and RA subjects

Impact of skin damage on health-related quality of life.

Increased anti-DNA Abs in 2KO-Bcl6TC mice.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

Number of microparticles (MPs) and distribution of MP surface markers in patients with SLE and HCs. Three aliquots of MPs were incubated with (1) anti-CD3,

Mean change from baseline over time in BILAG score,

Overall gene expression in monocyte subsets in patients and controls.

Tumors treated with anti-Flk-1 mAb have increased tumor cell apoptosis, reduced tumor cell proliferation, and increased tumor necrosis. s.c. Tumors treated.

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.

Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.

Dilution of anti-C6 monoclonal antibody shows the broader linear range of the Multiplex assay in comparison to standard ELISA. Shown is the dilution of.

HMQ1611 inhibited breast tumor growth in mice.

Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.

TLR9 deficiency leads to more severe impairment of endothelium-dependent vasorelaxation and promotes aberrant B cell phenotype in imiquimod-induced autoimmunity.

Measures of endothelial activation/dysfunction are associated with QRISK3. Measures of endothelial activation/dysfunction are associated with QRISK3. Increased.

Overall and recurrence-free survival.

(A–E) demonstrate a kidney biopsy from a patient with lupus nephritis (LN) class V. Representative micrographs: (A), an inflammatory infiltrate with T.

Presentation transcript:

Antinuclear antibody (ANA) patterns (using HEp-2 ANA assay kit) and anti-dsDNA (analysed by Crithidia luciliae assay) in sera of the lpr-water, lpr-CU and lpr-TU groups of mice. Antinuclear antibody (ANA) patterns (using HEp-2 ANA assay kit) and anti-dsDNA (analysed by Crithidia luciliae assay) in sera of the lpr-water, lpr-CU and lpr-TU groups of mice. (a) ANA patterns observed in sera (third bleed) (1:80 dilution) of the lpr-water group (A–C), lpr-CU group (D–F) and lpr-TU group (G–I); (b) anti-dsDNA observed in sera (first bleed) (1:100 dilution) of the lpr-water group (A–C), lpr-CU group (D–F) and lpr-TU group (G–I). Only results obtained from three animals are shown for each experimental group. CU, curcumin; TU, turmeric. Biji T Kurien et al. Lupus Sci Med 2015;2:e000114 ©2015 by Lupus Foundation of America